{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:26:29Z","timestamp":1788175589762,"version":"build-2803163510"},"reference-count":26,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sakari Alhopuro Foundation","award":["2025139"],"award-info":[{"award-number":["2025139"]}]},{"name":"Valtion tutkimusraha","award":["TYH2024323"],"award-info":[{"award-number":["TYH2024323"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,13]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine disorders globally, affecting 11\u201313% of women during reproductive age. PCOS is associated with an elevated risk of reproductive, metabolic, endocrine and mental health features. While lifestyle changes are first-line treatment for managing PCOS, metformin is often recommended for individuals with a body mass index (BMI) \u226525\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . The aim of the metformin use in polycystic ovary syndrome (MET-PCOS) trial is to determine whether a metformin dose of 1500\u2009mg per day or 2250\u2009mg per day is superior in managing biochemical and clinical outcomes in PCOS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      MET-PCOS is a double-blind randomised controlled trial with two arms. It will be carried out at the Reproductive Medicine Unit at Helsinki University Hospital, starting from November 2025. Participants aged 18\u201337 years with a BMI\u226525\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      meeting the updated 2023 Rotterdam criteria for a PCOS diagnosis will be included. The participants (n=184) will be allocated (1:1) to a metformin dose of 1500\u2009mg or 2250\u2009mg per day. Outcomes include anthropometry, metabolic outcomes, hyperandrogenism, polycystic ovary morphology, menstrual cyclicity, mental health and gastrointestinal adverse effects. Measurements for study endpoints will be undertaken at baseline, 14 and 26 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The Finnish Medicines Agency has authorised the clinical trial (FIMEA\/2025\/00755) and the Regional Committee Medical Research Ethics, Finland (T7323\/2024) has approved the trial protocol. This study will guide care providers in selecting the ideal metformin dose for individuals with PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT07120815\">NCT07120815<\/jats:ext-link>\n                      , EU trial number: 2023-509259-15-01.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-115656","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:55:59Z","timestamp":1773327359000},"page":"e115656","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct07120815","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hanna-Mari","family":"Hautam\u00e4ki","sequence":"first","affiliation":[{"name":"University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Savolainen-Peltonen","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina","family":"R\u00f6n\u00f6","sequence":"additional","affiliation":[{"name":"University of Helsinki, Helsinki, Finland"},{"name":"Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-7097","authenticated-orcid":false,"given":"Johanna","family":"Melin","sequence":"additional","affiliation":[{"name":"University of Helsinki, Helsinki, Finland"},{"name":"Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026062609362671000_16.3.e115656.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.05.003"},{"key":"2026062609362671000_16.3.e115656.2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew218"},{"key":"2026062609362671000_16.3.e115656.3","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh098"},{"key":"2026062609362671000_16.3.e115656.4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad463"},{"key":"2026062609362671000_16.3.e115656.5","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-8-41","article-title":"Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan","volume":"8","author":"Teede","year":"2010","journal-title":"BMC Med"},{"key":"2026062609362671000_16.3.e115656.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.3805"},{"key":"2026062609362671000_16.3.e115656.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102927","article-title":"International PCOS guideline clinical research priorities roadmap: a co-designed approach aligned with end-user priorities in a neglected women\u2019s health condition","volume":"78","author":"Teede","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026062609362671000_16.3.e115656.8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2283"},{"key":"2026062609362671000_16.3.e115656.9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2026062609362671000_16.3.e115656.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2026062609362671000_16.3.e115656.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2026062609362671000_16.3.e115656.12","doi-asserted-by":"crossref","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"2026062609362671000_16.3.e115656.13","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.9.1462"},{"key":"2026062609362671000_16.3.e115656.14","doi-asserted-by":"publisher","DOI":"10.1089\/met.2008.0034"},{"key":"2026062609362671000_16.3.e115656.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1974.tb03298.x"},{"key":"2026062609362671000_16.3.e115656.16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.6.1976"},{"key":"2026062609362671000_16.3.e115656.17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/cen.15038","article-title":"Healthcare and research priorities for women with polycystic ovary syndrome in the UK National Health Service: A modified Delphi method","volume":"100","author":"Al Wattar","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026062609362671000_16.3.e115656.18","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad098"},{"key":"2026062609362671000_16.3.e115656.19","doi-asserted-by":"crossref","first-page":"2516669","DOI":"10.1080\/0167482X.2025.2516669","article-title":"Mental state and health-related quality of life in patients with polycystic ovary syndrome under metformin therapy \u2013 a prospective study","volume":"46","author":"Hofmann","year":"2025","journal-title":"J Psychosom Obstet Gynecol"},{"key":"2026062609362671000_16.3.e115656.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-023-01195-1","article-title":"The effects of metformin on anti-M\u00fcllerian hormone levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"16","author":"Zhou","year":"2023","journal-title":"J Ovarian Res"},{"key":"2026062609362671000_16.3.e115656.21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/oby.21404","article-title":"Effects of clinically significant weight loss with exercise training on insulin resistance and cardiometabolic adaptations","volume":"24","author":"Swift","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"2026062609362671000_16.3.e115656.22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030424"},{"key":"2026062609362671000_16.3.e115656.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2012.03.004"},{"key":"2026062609362671000_16.3.e115656.24","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1210\/clinem\/dgae153","article-title":"Age-related Curves of AMH Using the Gen II, the picoAMH, and the Elecsys Assays in Women With Polycystic Ovary Syndrome","volume":"109","author":"Barbagallo","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026062609362671000_16.3.e115656.25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-0044-1786731","article-title":"Utility of Serum Anti-M\u00fcllerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis","volume":"42","author":"Piltonen","year":"2024","journal-title":"Semin Reprod Med"},{"key":"2026062609362671000_16.3.e115656.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00254-4"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-115656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:40:52Z","timestamp":1782492052000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-115656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjopen-2025-115656"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-115656","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}